02.15.24 -- Osmotic Controlled Release Oral Drug Delivery: A Closer Look

Learn how a biodegradable polymer platform that is compatible with many substrates can enable several applications as a drug eluting carrier with a wide variety of APIs.

Here, we share one of the best ways to ensure sterility in aseptic compounding operations and how 503A and 503B pharmacies can achieve the adaptability they need to scale their operations.

Finding the right formulation for a new product is a challenging part of research and development. Learn about powder rheology, an effective tool for accelerating formulation and development in pharma.

Discover how a partner who is committed to ensuring the safety of medical devices by mitigating the risk of chemical interaction with drugs is crucial for navigating the regulatory pathway to approval.

See how the gradient method allowances described in USP General Chapter <621> Chromatography, combined with a HPLC system, were employed for the USP monograph separation of abacavir sulfate.

Learn how a CDMO automatically created a comprehensive batch report model to drive their reporting and speed root cause identification of quality failures with an industrial DataOps software solution.

Conducting solid form screening early can help your team select and isolate the ideal lead polymorph to ensure manufacturability and stability while avoiding costs and hiccups down the road.

A pharma company was looking to partner with a CMO with commercial manufacturing capabilities, large-scale assets, multinational sites, and exemplary quality systems/U.S. FDA track record.

As the biotech industry has grown exponentially, so has the number of FDA clinical holds. Biotech companies need strategic planning to avoid or quickly resolve costly clinical holds.

Gain insight into how digital standardized tools can streamline your scaling processes and enable more accurate prediction and visualization of your scaling needs.

Find support for your infectious disease cellular response research, from detecting IgG in serum samples to identifying neutralizing antibodies.

The most common cause of downtime is the use of incorrect or out-of-date equipment. Explore considerations for improving your processes and increasing productivity.

New higher volume, higher viscosity pharmaceutical formulations for subcutaneous injection, alternatives to traditional intravenous treatment, enable chronic disease therapy in alternate settings.